Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | SORD | Q00796 | 1/20 | 0.38 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20135189 | 1.00 | KDM4E (0.43) | KDM4EGRM1LMNAL3MBTL1GPR119 | |
| SCHEMBL13703142 | 0.83 | KDM4E (0.46) | KDM4EGRM1LMNAL3MBTL1GPR119 | |
| SCHEMBL19035610 | 0.79 | GRM1 (0.47) | KDM4EGRM1LMNAL3MBTL1GPR119 | |
| SCHEMBL82255 | 0.76 | HDAC1 (0.40) | GPR119CDK4EIF2AK4HDAC1 | |
| SCHEMBL28478019 | 0.76 | GRM1 (0.44) | KDM4EGRM1LMNAL3MBTL1GPR119 | |
| SCHEMBL20064219 | 0.76 | GRM1 (0.44) | KDM4EGRM1LMNAL3MBTL1GPR119 | |
| SCHEMBL31357440 | 0.76 | GRM1 (0.44) | KDM4EGRM1LMNAL3MBTL1GPR119 | |
| SCHEMBL28478020 | 0.76 | GRM1 (0.44) | KDM4EGRM1LMNAL3MBTL1GPR119 | |
| SCHEMBL13149760 | 0.75 | PLD1 (0.51) | KDM4EGRM1HDAC1 | |
| SCHEMBL12525383 | 0.75 | KDM4E (0.50) | KDM4EGRM1LMNAL3MBTL1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | KDM4E 2865/4885GRM1 3550/4885LMNA 2866/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | KDM4E 3393/4885GRM1 2839/4885LMNA 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.